BlackRock Fund Advisors’s Blueprint Medicines BPMC Stock Holding History

BlackRock Fund Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$28.8M	Buy	1,025,225 +113,437	+12%	+$3.42M	0.01%	1982
2016 Q3	$27.1M	Buy	911,788 +39,995	+5%	+$994K	0.01%	1924
2016 Q2	$17.7M	Buy	871,793 +277,781	+47%	+$5.05M	﹤0.01%	2095
2016 Q1	$10.7M	Buy	594,012 +23,355	+4%	+$405K	﹤0.01%	2303
2015 Q4	$15M	Buy	570,657 +328,847	+136%	+$7.4M	﹤0.01%	2202
2015 Q3	$5.16M	Sell	241,810 -3,445	-1%	-$95.3K	﹤0.01%	2792
2015 Q2	$6.5M	Buy	+245,255	New	+$7M	﹤0.01%	2764

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock Fund Advisors's BPMC Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Blueprint Medicines (BPMC) stake by 12% in Q4 2016, buying an estimated $3.42M and bringing the position to 1,025,225 shares worth $28.8M. The position accounts for 0.01% of the portfolio, ranked #1982.

BlackRock Fund Advisors first reported a position in BPMC in Q2 2015 and has held it in 7 quarters since. 103 funds tracked by Wall St. Rank hold BPMC as of Q4 2016.

BlackRock Fund Advisors held 1,025,225 shares of Blueprint Medicines worth $28.8M as of Q4 2016.
BlackRock Fund Advisors bought 113,437 Blueprint Medicines shares in Q4 2016, an estimated $3.42M.
Blueprint Medicines made up 0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #1982 holding.
BlackRock Fund Advisors first reported a position in Blueprint Medicines in Q2 2015 and has held it in 7 quarters since.
103 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.